<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334708</url>
  </required_header>
  <id_info>
    <org_study_id>17-527</org_study_id>
    <nct_id>NCT03334708</nct_id>
  </id_info>
  <brief_title>A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma</brief_title>
  <official_title>Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weizmann Institute of Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a minimally invasive test to diagnose pancreatic&#xD;
      cancer at early stages of disease and monitor response to treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in biomarkers to determine sensitivity and specificity of the assay to diagnose early stage pancreatic cancer</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreatic Diseases</condition>
  <condition>Pancreatitis</condition>
  <condition>Pancreatic Cyst</condition>
  <arm_group>
    <arm_group_label>Locally Advanced or Metastatic Pancreatic Cancer Cohort</arm_group_label>
    <description>For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Benign Pancreatic Pathology Control Cohort</arm_group_label>
    <description>For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Benign Pancreatic Path,IPMC &amp; Pancreatic Cyst Ctrl</arm_group_label>
    <description>For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>For normal controls, blood specimens will be drawn once at study baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:&#xD;
Patients and controls weighing 50kg or more&#xD;
For draw amounts up to 50mL, there is no required hemoglobin threshold.&#xD;
For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period.&#xD;
Patients and controls weighing &lt; 50kg&#xD;
For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time.</description>
    <arm_group_label>Acute Benign Pancreatic Pathology Control Cohort</arm_group_label>
    <arm_group_label>Chronic Benign Pancreatic Path,IPMC &amp; Pancreatic Cyst Ctrl</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Locally Advanced or Metastatic Pancreatic Cancer Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tumor Tissue Collection</intervention_name>
    <description>Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere</description>
    <arm_group_label>Acute Benign Pancreatic Pathology Control Cohort</arm_group_label>
    <arm_group_label>Chronic Benign Pancreatic Path,IPMC &amp; Pancreatic Cyst Ctrl</arm_group_label>
    <arm_group_label>Locally Advanced or Metastatic Pancreatic Cancer Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cyst Fluid</intervention_name>
    <description>Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere</description>
    <arm_group_label>Chronic Benign Pancreatic Path,IPMC &amp; Pancreatic Cyst Ctrl</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be analyzed for various biomarkers. Initial biomarkers to be tested&#xD;
      include proteins and proteases, functional DNA repair assays, exosomes, stromal elements,&#xD;
      circular RNAs (cRNA) and circulating tumor DNA (ctDNA).&#xD;
&#xD;
      Tissue will be utilized from already planned. Biopsy tissue is expected to be available for&#xD;
      virtually all PDAC patients, occasionally for IPMN and cysts patients, rarely for&#xD;
      pancreatitis and never for healthy controls.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Potential research subjects in the PDAC and benign pancreatic disease cohorts will be&#xD;
        identified by a member of the patient's treatment team, the principal investigator, or&#xD;
        research team at participating institutions. If the investigator is a member of the&#xD;
        treatment team, s/he will screen their patients' medical records for suitable research&#xD;
        study participants and discuss the study and their potential for enrolling in the research&#xD;
        study. The investigator will use information provided by the patient and/or medical record&#xD;
        to confirm that the patient is eligible and contact the patient regarding study enrollment.&#xD;
        Healthy controls will be recruited from patients from outpatient primary care clinics at&#xD;
        non-MSK sites and volunteers from which may include the staffs members at collaborating&#xD;
        sites.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria&#xD;
&#xD;
          -  Histological or cytological confirmed diagnosis of locally advanced or metastatic&#xD;
             pancreatic adenocarcinoma by the enrolling institution&#xD;
&#xD;
          -  Patient planning to receive systemic treatment&#xD;
&#xD;
          -  For stage IV patients, if adjuvant chemotherapy and/or chemoradiation therapy was&#xD;
             received for AJCC Stage I-III pancreatic adenocarcinoma, patients are eligible if the&#xD;
             last systemic therapy was given more than 6 months before initiation of currently&#xD;
             planned systemic therapy&#xD;
&#xD;
          -  Hemoglobin &gt; 8&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  A minimum age of 18 years old&#xD;
&#xD;
          -  Willing to provide permission to obtain banked tumor tissue for analysis (previous&#xD;
             biopsies or surgical material). New tumor biopsies are not required for entrance into&#xD;
             the protocol.&#xD;
&#xD;
        Cohort 2: Operable Pancreatic Cancer Cohort Inclusion Criteria&#xD;
&#xD;
          -  Histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the&#xD;
             enrolling institution&#xD;
&#xD;
          -  Patient planned to undergo upfront resection&#xD;
&#xD;
          -  No pre-operative systemic therapy nor chemoradiation therapy planned&#xD;
&#xD;
          -  Hemoglobin &gt; 8&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  A minimum age of 18 years old&#xD;
&#xD;
          -  Willing to provide permission to obtain banked tumor tissue for analysis (previous&#xD;
             biopsies or surgical material). New tumor biopsies are not required for entrance into&#xD;
             the protocol.&#xD;
&#xD;
        Cohort 3: Acute Benign Pancreatic Pathology Control Inclusion Criteria&#xD;
&#xD;
          -  Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the&#xD;
             enrolling institution&#xD;
&#xD;
          -  Hemoglobin &gt; 8&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  A minimum age of 18 years old&#xD;
&#xD;
        Cohort 4: Chronic Benign Pancreatic Pathology Control Inclusion Criteria&#xD;
&#xD;
          -  Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic&#xD;
             pathology by the enrolling institution&#xD;
&#xD;
          -  Hemoglobin &gt; 8&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  A minimum age of 18 years old&#xD;
&#xD;
        Cohort 5: IPMN Control Inclusion Criteria&#xD;
&#xD;
          -  Confirmed diagnosis of IPMN without high risk features by the enrolling institution&#xD;
&#xD;
          -  A minimum age of 18 years old&#xD;
&#xD;
        Cohort 6: Pancreatic Cyst Control Inclusion Criteria&#xD;
&#xD;
          -  Confirmed diagnosis of benign pancreatic cyst by the enrolling institution&#xD;
&#xD;
          -  A minimum age of 18 years old&#xD;
&#xD;
        Cohort 7: Healthy Control Inclusion Criteria&#xD;
&#xD;
          -  A minimum age of 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria&#xD;
&#xD;
          -  Prior therapy for advanced/metastatic disease&#xD;
&#xD;
          -  Prior history of another malignancy&#xD;
&#xD;
          -  Adjuvant therapy for resected disease within the last 6 months&#xD;
&#xD;
          -  Active second malignancy&#xD;
&#xD;
          -  Any medical or psychiatric condition that may interfere with ability to comply with&#xD;
             protocol procedures&#xD;
&#xD;
          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning&#xD;
             for genetic predisposition to cancer&#xD;
&#xD;
        Cohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria&#xD;
&#xD;
          -  Neoadjuvant chemotherapy or radiation therapy is planned&#xD;
&#xD;
          -  Prior history of another malignancy, except non-melanoma skin cancer&#xD;
&#xD;
          -  Active second malignancy&#xD;
&#xD;
          -  Any medical or psychiatric condition that may interfere with ability to comply with&#xD;
             protocol procedures&#xD;
&#xD;
          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning&#xD;
             for genetic predisposition to cancer&#xD;
&#xD;
        Cohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria&#xD;
&#xD;
          -  Active or prior malignancy, except prior non-melanoma skin cancer&#xD;
&#xD;
          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning&#xD;
             for genetic predisposition to cancer&#xD;
&#xD;
          -  Any medical or psychiatric condition that may interfere with ability to comply with&#xD;
             protocol procedures&#xD;
&#xD;
        Cohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria&#xD;
&#xD;
          -  Active or prior malignancy, except prior non-melanoma skin cancer&#xD;
&#xD;
          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning&#xD;
             for genetic predisposition to cancer&#xD;
&#xD;
          -  Any medical or psychiatric condition that may interfere with ability to comply with&#xD;
             protocol procedures&#xD;
&#xD;
        Cohort 5: IPMN Control Exclusion Criteria&#xD;
&#xD;
          -  IPMN with high risk features or planned resection&#xD;
&#xD;
          -  Active or prior malignancy, except prior non-melanoma skin cancer&#xD;
&#xD;
          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning&#xD;
             for genetic predisposition to cancer&#xD;
&#xD;
          -  Any medical or psychiatric condition that may interfere with ability to comply with&#xD;
             protocol procedures&#xD;
&#xD;
        Cohort 6: Pancreatic Cyst Control Exclusion Criteria&#xD;
&#xD;
          -  Active or prior malignancy, except prior non-melanoma skin cancer&#xD;
&#xD;
          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning&#xD;
             for genetic predisposition to cancer&#xD;
&#xD;
          -  Any medical or psychiatric condition that may interfere with ability to comply with&#xD;
             protocol procedures&#xD;
&#xD;
        Cohort 7: Healthy Control Exclusion Criteria&#xD;
&#xD;
          -  Active or prior malignancy, except prior non-melanoma skin cancer&#xD;
&#xD;
          -  Proven to be a carrier of a cancer susceptibility gene or family history concerning&#xD;
             for genetic predisposition to cancer&#xD;
&#xD;
          -  Any medical or psychiatric condition that may interfere with ability to comply with&#xD;
             protocol procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kenneth Yu, MD</last_name>
    <phone>646-888-4188</phone>
    <email>yuk1@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Kelson, MD</last_name>
    <phone>646-888-4179</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (All protocol activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Yu, MD, M.Sc.</last_name>
      <phone>646-888-4188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (All protocol activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Yu, MD, M.Sc.</last_name>
      <phone>646-888-4188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cold Springs Harbor Laboratory (Specimen Analysis)</name>
      <address>
        <city>Cold Spring Harbor</city>
        <state>New York</state>
        <zip>11724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Tuveson, MD, PhD</last_name>
      <phone>516-367-5246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Yu, MD, M.Sc.</last_name>
      <phone>646-888-4188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (All protocol activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Yu, MD, M.Sc.</last_name>
      <phone>646-888-4188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Simeone, MD</last_name>
      <phone>212-731-6150</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Yu, MD</last_name>
      <phone>646-888-4188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (All protocol activitie)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Yu, MD, M.Sc.</last_name>
      <phone>646-888-4188</phone>
    </contact>
    <contact_backup>
      <last_name>S</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Lyden, MD</last_name>
      <phone>212-746-6565</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (All protocol activities)</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Yu, MD, M.Sc.</last_name>
      <phone>646-888-4188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sha'are Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ephrat Levy-Lahad, PhD</last_name>
      <phone>646-497-2600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weizmann Institute of Science</name>
      <address>
        <city>Reáº–ovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Avigdor Scherz, PhD</last_name>
      <phone>972 8-934-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talia Golan, MD</last_name>
      <phone>03-5303295</phone>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>17-257</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Cyst</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

